Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in Primary Sclerosing Cholangitis (PSC)
NCT03333928Phase 2Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Feb 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of berberine ursodeoxycholate in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Absolute Change in Serum Alkaline Phosphatase at 18 weeks. Started Feb 2018; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03333928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333928.